Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.66
-0.09 (-1.57%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States.

The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich’s ataxia, as well as other drugs for the treatment of cardiac and other diseases.

In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid.

The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida.

Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Solid Biosciences Inc.
Solid Biosciences logo
Country United States
Founded 2013
IPO Date Jan 26, 2018
Industry Biotechnology
Sector Healthcare
Employees 88
CEO Alexander Cumbo

Contact Details

Address:
500 Rutherford Avenue, Third Floor
Charlestown, Massachusetts 02129
United States
Phone 617 337 4680
Website solidbio.com

Stock Details

Ticker Symbol SLDB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001707502
CUSIP Number 83422E105
ISIN Number US83422E2046
Employer ID 90-0943402
SIC Code 2836

Key Executives

Name Position
Ilan Ganot Co-founder, Strategic Advisor to the Chief Executive Officer and Director
Alexander G. Cumbo President, Chief Executive Officer and Director
Ian F. Smith A.C.A., C.P.A. Executive Chair
Kevin Tan C.F.A. Chief Financial Officer and Treasurer
David Tyronne Howton Jr., J.D. Chief Operating Officer, General Counsel and Secretary
Annie Ganot Co-Founder and Head of Patient Advocacy
Paul Herzich Chief Technology Officer
Allison Bogosian J.D. Senior Vice President of Human Resources
Dr. Jessie Hanrahan Ph.D. Chief Regulatory Officer
Dr. Shuli Kulak M.D. Head of Corporate Strategy and Business Development

Latest SEC Filings

Date Type Title
Nov 1, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 13, 2024 10-Q Quarterly Report
Aug 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jun 12, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jun 11, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jun 11, 2024 8-K Current Report
Jun 11, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 5, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 17, 2024 EFFECT Notice of Effectiveness
May 15, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933